 Pfizer Inc NYSE:PFE is to pay US5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc NASDAQ:GBT GBT as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US68.50 per GBT share, which represents a 7.3 premium over Fridays closing price and nearly 43 over Thursdays closing price. 